Zoono's share price slumps after covid serves mixed results

Zoono's share price slumps after covid serves mixed results
A Transport for London worker sprays anti viral solution Zoono-71 inside a tube train north London in May 2020.
Denise McNabb
Covid-19 is turning out to be a double-edged sword for ASX-listed New Zealand antimicrobials company, Zoono Group. Its hand sanitiser sales had benefited from the virus, but chief executive Paul Hyslop said demand for the company’s surface sanitising spray has been hampered by lockdowns leaving offices empty and delaying the need for disinfection protection.“While the company has overall undoubtedly benefited from the impact of the covid-19 pandemic, in many respects the opposite has been the case in the review period in that t...

More Markets

Air NZ expects 1H loss of $30m to $55m
Markets

Air NZ expects 1H loss of $30m to $55m

According to Air NZ, it had anticipated a 2% to 3% revenue uplift.

Alan Bougen corrects statement with regard to Comvita
Markets

Alan Bougen corrects statement with regard to Comvita

Bougen said some of his previous statements "may have been ambiguous".

SkyCity on cusp of NZICC takeover
Markets

SkyCity on cusp of NZICC takeover

What can the business and tourism industry expect in the first year?  

No respite for the NZ dollar
Economy

No respite for the NZ dollar

Easing trade tensions isn’t helping the NZ dollar.